Key facts
- Sweetch’s last known valuation is $47.0M (Jul 2021).
- It has raised $37.2M; the latest was Later Stage VC in May 2025.
- Notable investors include OurCrowd, Entrée Capital, Decacorn Capital, Noaber Ventures, FinTLV Ventures — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Sweetch
- ·The full record, as it builds
Funding rounds
No funding rounds for Sweetch are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sweetch
Developer of a hyper-personalized engagement platform intended to improve clinical outcomes for people with chronic conditions. The company's platform allows individuals to achieve their health goals with hyper-personalized recommendations in the right time, tone, and real-world context every step of the way throughout their health journey, enabling pharmaceutical companies, device manufacturers, payers, and healthcare providers to build continuous relationships and engage with every individual patient with chronic conditions, at scale.
- Sector
- Healthcare
- HQ
- Ramat Gan, Israel
- Founded
- 2013
- Employees
- 49
- Website
- sweetch.com/
- Ownership
- Privately Held (backing)
Sweetch doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sweetch shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sweetch in its N-PORT filings yet. We sweep new filings monthly.